Gemigliptin-metformin combo leads to better glycemic control without hypoglycemia risk
South Korea: Treatment with gemigliptin-metformin combination therapy led to the higher achievement of the glycemic target without weight gain or hypoglycemia, better than with glimepiride-metformin, a recent study has shown. The improvements might be linked with beneficial changes in gut microbiota.
"In our randomized controlled trial (RCT) of drug-naïve Korean patients with type 2 diabetes, 77% of the patients given the gemigliptin–metformin therapy achieved the target goal of HbA1c ≤ 7.0% (53 mmol/mol)," the researchers wrote in their study published in the journal Nutrients. They explained, "this approach favourably changed the amino acid levels and gut microbiota, indicating potential improvements in anti-inflammatory effects and pancreatic β-cell function."
"Our findings indicate that changes in the gut microbiota are critical for augmenting the efficacy of gemigliptin therapy. This may apply to DPP-4 inhibitors in more general terms."
Changes in humans' gut microbiota can impact the safety and efficacy of medications. Among anti-diabetic drugs, incretin-based therapy such as dipeptidyl peptidase 4 inhibitors (DPPi) might affect the gut microbiome related to glucose metabolism. Soo Lim from Seoul National University College of Medicine in Seongnam, Republic of Korea, and colleagues conducted a randomized, controlled, active-competitor study to compare the effects of gemigliptin–metformin versus glimepiride–metformin combinations as initial therapies on glucose homeostasis and gut microbiota in drug-naive patients with type 2 diabetes.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.